| Title | Organization | Keywords | Activity Code | FOA | LOI Due Date | Application Due Date |
|---|---|---|---|---|---|---|
| (NOSI): Administrative Supplements for Contemporary Modifiable Exposures and Cancer Across the Life Course and Cancer Control Continuum | National Cancer Institute | Artificial intelligence, AI, Early detection, screening, diagnosis, risk prediction | Admin Supp | NOT-CA-24-030 | 4/22/2024 | |
| (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments | National Cancer Institute | career development, disabilities, diversity, inclusion , | R21,R01,R03 | NOT-CA-22-038 | 5/7/2024 | |
| (NOSI): Administrative Supplements for NCI Global Oncology Mentored Research | National Cancer Institute | health disparities, prevention, diagnosis, treatment, survivorship, Native American, Alaska Native | Admin Supp | NOT-CA-24-028 | 5/15/2024 | |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | National Institutes of Health | clinical trials, early phase, treatment, diagnosis, innovative therapies | PAR-24-085 | 1/5/2024 | 6/5/2024 | |
| (NOSI): Administrative Supplements for Assessing and Enhancing Survivorship Care | National Cancer Institute | early career, survivorship, health care, | admin supplement | NOT-CA-24-041 | 6/5/2024 | |
| Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | National Cancer Institute | cancer informatics, clinical trials (optional), technology development, data management, research tools | RFA-CA-24-019 | 5/12/2024 | 6/11/2024 | |
| Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) | National Cancer Institute | cancer informatics, clinical trials (optional), technology development, early adopters, innovation | RFA-CA-24-018 | 5/12/2024 | 6/11/2024 | |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) | National Cancer Institute | cancer informatics, clinical trials (optional), technology development, proof-of-concept, feasibility | RFA-CA-24-017 | 5/12/2024 | 6/11/2024 | |
| Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) | National Cancer Institute | cancer informatics, algorithms, machine learning, artificial intelligence, data analysis, modeling | RFA-CA-24-016 | 5/12/2024 | 6/11/2024 | |
| NCI Mentored Research Scientist Development Award (K01) | National Cancer Institute | early career development, independent research | 6/12/2024 | |||
| NCI Mentored Research Scientist Development Award to Promote Diversity (K08 No Independent Clinical Trials) | National Cancer Institute | early-career, mentored, diversity, | PAR-21-300 | 6/12/2024 | ||
| (NOSI): Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy | National Cancer Institute | immunotherapy, Basic mechanisms, irAEs | R01,R21,K99/R00,K01,K08,K22,R03,R15 | NOT-CA-22-063 | 7/4/2024 | |
| Ruth L. Kirschstein National Research Service Award (NRSA) Individual Predoctoral Fellowship to Promote Diversity in Health-Related Research (Parent F31-Diversity)? | National Cancer Institute | early career, predoctoral, diversity | PA-23-271 | 8/8/2024 | ||
| (NOSI): National Cancer Institute SBIR/STTR Program Announcement Regarding Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings | National Cancer Institute | low-resource settings, minorities, community, clinical trials | R43/R44,R41/R42 | NOT-CA-21-062 | 9/6/2024 | |
| (NOSI): Dietary Effects on Nutrient Sensing Pathways in Tumor Etiology and Prevention | National Cancer Institute | Low-resource settings, affordable, dietary effects, tumor development, nutritional strategies, oncometabolites, signaling pathways, gene regulation, cellular processes, cell fate decisions, metabolic homeostasis, stem cell changes, systemic or local inflammation, pro-tumorigenic environment, treatment-related cardiotoxicity, early detection, childhood cancer survivors | K22,K08,R15,R01,R21,K99/R00, | NOT-CA-21-121 | 9/7/2024 | |
| (NOSI): Research on the Etiology, Early Detection, Screening and Prevention of Early-Onset Colorectal Cancer | National Cancer Institute | Early detection, disparities, diagnosis, underserved populations, underrepresented populations | K01,R01,K22,K08,R21,U34,K99/R00,P01,R34 | NOT-CA-23-018 | 9/7/2024 | |
| (NOSI): Mechanisms Driving Obesity and Prostate Cancer Risk | National Cancer Institute | surveillance methods, data collection, analysis, dissemination, trends, patterns, Early detection, emerging threats | R01,K99/R00,R21,K08,K22 | NOT-CA-23-089 | 9/7/2024 | |
| Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional) | National Cancer Institute | Health disparities | U54 | RFA-CA-24-020 | 8/26/2024 | 9/26/2024 |
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | National Cancer Institute | biospecimens, biobanking, tissue preservation, biomarkers, genomics, proteomics, precision medicine | RFA-CA-24-010 | 9/1/2024 | 10/1/2024 | |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | National Cancer Institute | molecular analysis, cellular analysis, diagnostics, therapeutics, drug development, precision medicine, nanotechnology | RFA-CA-24-008 | 9/1/2024 | 10/1/2024 | |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | National Cancer Institute | biospecimen science, technology development, validation, biobanking, tissue preservation, biomarkers, precision medicine | RFA-CA-24-011 | 9/1/2024 | 10/1/2024 | |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | National Cancer Institute | molecular analysis, cellular analysis, technology development, validation, diagnostics, therapeutics, drug development, precision medicine | RFA-CA-24-009 | 9/1/2024 | 10/1/2024 | |
| (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment | National Cancer Institute | Interprofessional teamwork, Interventions, Collaboration | R03,R01,R21,P01 | NOT-CA-22-014 | 10/8/2024 | |
| (NOSI): Disparities Affecting Healthcare Utilization and Health Outcomes Among Childhood Cancer Survivors | National Cancer Institute | Disparities, childhood cancer survivors, Interventions | R01,R21,P01,R03 | NOT-CA-22-029 | 10/8/2024 | |
| (NOSI): Improving Outcomes in Cancer Treatment-Related Cardiotoxicity | National Cancer Institute | cardiotoxicity, heart health, collaboration, early detection, prevention | R01,R03,R21,P01 | NOT-CA-22-001 | 11/5/2024 | |
| (NOSI): Career Development Opportunities for Research Within the Mission of the Division of Cancer Prevention at the National Cancer Institute | National Cancer Institute | Early-career, academic scientists, diagnostics, therapeutics, | K22,K08,K99/R00,K01 | NOT-CA-23-035 | 11/12/2024 | |
| The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed) | National Cancer Institute | NCI, Predoctoral, Postdoctoral, training, Fellow Transition Award, Early Stage | RFA-CA-23-042 | 11/19/2024 | ||
| Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional) | National Cancer Institute | Kaposi sarcoma herpesvirus, virus, vaccine, therapeutic, innovation | RFA-CA-24-006 | 11/4/2023 | 12/4/2024 | |
| (NOSI): Technologies and Informatics Tools for Cancer Metabolomics | National Cancer Institute | Informatics, Metabolomics, Molecular Analysis, lipidomics, low-resource | R33,R61,R21,U24,U01 | NOT-CA-22-083 | 12/30/2024 | |
| (NOSI): Technology Development for Cancer Control and Population Science Research | National Cancer Institute | Microbiome, development, progression, therapeutic targets | U01,R21,R61,R33,U24 | NOT-CA-23-037 | 12/30/2024 | |
| (NOSI): Adaptive Biomaterials for Cancer Biology | National Cancer Institute | Adaptive biomaterials, Biology, biomaterials, diagnostic, therapeutic | R01,K22,K99/R00 | NOT-CA-23-030 | 5/6/2025 | |
| (NOSI): Administrative Supplements for Enhancing Recruitment and Retention of Diverse Populations to Cancer Screening, Cancer Prevention and Symptom Management Clinical Trials | National Cancer Institute | Innovative technologies, prevention, early detection, new technologies, | Admin Supp | NOT-CA-23-071 | 6/30/2025 | |
| (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers | National Cancer Institute | Early detection, Advanced biomarkers, High-risk individuals, early detection | R43/R44,R21,R01,UH2/UH3,R41/R42,U01 | NOT-CA-23-004 | 7/1/2025 | |
| (NOSI): Pragmatic Trials in Low Resource Settings | National Cancer Institute | clinical trials, Low-resource settings, interventions, routine healthcare, underserved populations, health disparities | UG3/UH3 | NOT-CA-23-078 | 11/17/2025 | |
| (NOSI): RNA Modifications in Cancer Biology | National Cancer Institute | Precision prevention, AI, high risk, prevention strategies | R33,R21,U01,R61,R03 | NOT-CA-23-060 | 1/7/2026 | |
| (NOSI): Epidemiologic Studies to Assess the Impact of Incretin Mimetics on New and Recurrent Cancer Risk? | National Cancer Institute | disparities, epidemiology, | NOT-CA-24-037 | 5/9/2026 | ||
| (NOSI): Research on HIV-associated Malignancies | National Cancer Institute | Social, behavioral , communication, education, strategies, prevention, early detection, treatment, health disparities | R21,R01 | NOT-CA-23-070 | 9/7/2026 | |
| (NOSI): Exploratory Cancer Immunology Projects and Technologies (ExCITe) | National Cancer Institute | Clinical decision support tools, CDSTs, care delivery, clinical decision-making, patient outcomes | R21 | NOT-CA-24-016 | 11/16/2026 | |
| (NOSI): National Cancer Institute Entrepreneurial Education Programs to Facilitate Commercialization of Cancer Relevant Technologies | National Cancer Institute | Social determinants, health disparities, SDOH, evaluating interventions | R25 | NOT-CA-24-001 | 1/7/2027 | |
| (NOSI): Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer | National Cancer Institute | Cannabis, cannabinoids, interception, therapeutic applications, biology | K22,R01,K08,K01,R21,R03,K99/R00 | NOT-CA-22-085 | 7/4/2027 | |
| (NOSI): Research Projects to Develop Oncoaging Models for Cancer Research | National Cancer Institute | Equity, equitable care, interventions | R21,R01 | NOT-CA-23-092 | 7/30/2027 | |
| (NOSI): National Cancer Institute Supports Applications for the Mentored Research Scientist Development Awards (K01) Within the Mission of the Division of Cancer Control and Population Sciences | National Cancer Institute | Mentored Research, Development Awards, Population Sciences, susceptibility factors, genetic, epigenetic, immunological, inflammatory, hormonal, social, cultural, ethnic, Intervention development, obacco, alcohol, diet, physical activity, behavioral, psychosocial | K01 | NOT-CA-24-022 | 5/7/2029 | |
| (NOSI): National Cancer Institute Supports Applications for the Mentored Research Scientist Development Awards (K01) Within the Mission of the Division of Cancer Prevention | National Cancer Institute | Mentored Research, Development Awards, Down syndrome | K01 | NOT-CA-24-023 | 5/7/2029 |
Can’t find what you’re looking for? Please contact researchdevelopment@cancer.ufl.edu for assistance in finding additional funding opportunities.
